Novo Nordisk opjusterer årsforventning -Sådan leverede NN i Q1 – i forhold til analytikernes forventning
6/5 08:04
Ledelsen skriver: The 2026 outlook is raised, driven by increased expectations for GLP-1 product sales. Adjusted sales growth for 2026, which excludes the 340B provision reversal, is now expected to be -4 to -12% at CER. Adjusted operating profit growth, also excluding the 340B provision reversal, is now expected to be -4 to -12% at […]...